SetPoint Medical key facts
as of Oct 2026- Developer of an implantable bioelectronic medical device designed to modulate neuroimmune pathways for reducing inflammation and restoring immunologic balance in chronic autoimmune conditions.
- SetPoint Medical is valued at approximately $480.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $580.5M across 7 recorded rounds; the latest was Later Stage VC (Series D) ($115.5M) in Oct 2025.
- Notable investors include Viking Global Investors, New Enterprise Associates, Norwest, Catalio Capital Management, Flare Capital Partners — 29 tracked in total.
- SetPoint Medical has filed 10 Form Ds with the SEC since 2011, most recently Apr 2025 ($115.0M sold to 23 investors).
- Status: Privately Held (backing).
Valued at $480.0M at its later-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 29 names
- ·Watch SetPoint Medical: the Monday email on marks, rounds and moves
SetPoint Medical funding rounds
7 roundsWho backs SetPoint Medical
29+SetPoint Medical valuation
SetPoint Medical was valued at $480 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has SetPoint Medical raised?
SetPoint Medical has raised $581 million across 7 recorded rounds since 2011. The largest was a $64.4 million later-stage round in Oct 2020; the most recent was an $116 million Series D in Oct 2025.
SetPoint Medical has filed 10 Form Ds with the SEC since 2011, most recently in Apr 2025 ($115 million sold to 23 investors).
SetPoint Medical investors
29 investors are on record for SetPoint Medical, including Viking Global Investors, New Enterprise Associates, Norwest and Catalio Capital Management. By type, the record holds 5 venture capital firms, 1 family office and 1 asset manager. The Series D in Oct 2025 drew 17 investors.
Comparable companies
Comparable therapeutic devices names by valuation on PrivateMarketView: Saluda Medical ($435 million), LightForce ($400 million) and Soufflé Therapeutics ($345 million).
About SetPoint Medical
Developer of an implantable bioelectronic medical device designed to modulate neuroimmune pathways for reducing inflammation and restoring immunologic balance in chronic autoimmune conditions. The company delivers targeted electrical stimulation to the vagus nerve through a small, wireless implant programmed to provide daily therapy automatically with low maintenance, enabling healthcare providers and patients managing autoimmune diseases such as rheumatoid arthritis to access an alternative to traditional drug treatments with potentially reduced risk and treatment burden.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Valencia, CA, United States
- Founded
- 2007
- Employees
- 90
- Website
- setpointmedical.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.